𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Delivery and therapeutic potential of human granzyme B

✍ Scribed by Florian C. Kurschus; Dieter E. Jenne

Book ID
110746725
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
259 KB
Volume
235
Category
Article
ISSN
0105-2896

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Drug delivery of siRNA therapeutics: pot
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems
✍ Daniela Reischl; Andreas Zimmer πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 539 KB

Gene therapy is a promising tool for the treatment of human diseases that cannot be cured by rational therapies. The major limitation for the use of small interfering RNA (siRNA), both in vitro and in vivo, is the inability of naked siRNA to passively diffuse through cellular membranes due to the st

Delivery of therapeutic proteins
Delivery of therapeutic proteins
✍ Dipak S. Pisal; Matthew P. Kosloski; Sathy V. Balu-Iyer πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 298 KB

The safety and efficacy of protein therapeutics are limited by three interrelated pharmaceutical issues, in vitro and in vivo instability, immunogenicity and shorter half-lives. Novel drug modifications for overcoming these issues are under investigation and include covalent attachment of poly(ethyl

Therapeutic potential of Galectin-9 in h
Therapeutic potential of Galectin-9 in human disease
✍ Valerie R. Wiersma; Marco de Bruyn; Wijnand Helfrich; Edwin Bremer πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 714 KB

In recent years, an important role has emerged for the glycan‐binding protein Galectin‐9 (Gal‐9) in health and disease. In normal physiology, Gal‐9 seems to be a pivotal modulator of T‐cell immunity by inducing apoptosis in specific T‐cell subpopulations. Because these T‐cell populations are associa